The Motley Fool

Ionis CEO: $3B Tryngolza Opportunity and the Next Wave of RNA Drugs

Ionis Pharmaceuticals CEO Brett Monia discussed the company’s near‑term catalysts, focusing on the upcoming FDA decision for Olezarsen, branded Tryngolza, in severe hypertriglyceridemia (SHTG). The drug, already approved for the rare genetic disease familial chylomicronemia syndrome, demonstrated an 85% reduction in acute pancreatitis events in a Phase 3 trial, prompting breakthrough therapy designation and a PDUFA date of June 30. Monia highlighted that Tryngolza lowered triglycerides by more than 70% and pushed the majority of patients below the 500 mg/dL threshold, establishing a high efficacy bar. He announced an upgraded U.S. peak‑sales outlook of over $3 billion, explicitly factoring in competition from Arrowhead’s siRNA candidate Plozasiran, and emphasized the durability of first‑mover advantage and the market’s capacity for multiple players. The discussion also turned to Pelacarsen, Ionis’s Lp(a)‑lowering asset partnered with Novartis. The HORIZON outcomes trial, enrolling 8,300 patients, will be read out later this year and could confirm Lp(a) as a modifiable cardiovascular risk factor. Monia noted that a positive readout would unlock a multi‑billion‑dollar royalty stream and reinforce Ionis’s reputation as a pioneer in RNA therapeutics. Finally, Monia outlined Ionis’s strategic shift toward siRNA platforms, citing a follow‑on siRNA candidate for SHTG that aims for semi‑annual dosing. By diversifying its technology stack and building next‑generation molecules, Ionis seeks to protect its market leadership and extend franchise value for decades.